Has James Orsini, MD received payments from drug or device companies?

Yes. Drug and device makers reported $38,261 in general payments to James Orsini, MD across 243 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean James Orsini, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about James Orsini, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

James Orsini, MD

Hematology & Oncology · Belleville, NJNPI 1922084185

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $27,785 of the $38,261 with a category attached, or 72.6%. Seagen Inc. accounts for 65.3% of it on its own, with 43 other manufacturers making up the rest. Reporting peaked in 2021 at $18,251 and has fallen 95.5% since, to $824 in 2025. Among hematology & oncology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$38,261in general payments, 2019–2025

Across 243 payments — averaging $157.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Seagen Inc.$25K
Astellas Pharma US Inc$10K
AstraZeneca$495
Incyte Corporation$366
E.r. Squibb & Sons, L.L.C.$273
Johnson & Johnson$223
plus $2K from 38 others

$537,586in research payments, 2019–2025

Across 33 payments — averaging $16,290 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novartis$491K
Mirati Therapeutics, Inc.$16K
E.r. Squibb & Sons, L.L.C.$16K
Astrazeneca UK Limited$12K
Amgen$2K

What the payments were for

Speaking & faculty fees$27,78573%
Travel & lodging$5,53614%
Food & beverage$4,11411%
Education$8262%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Seagen Inc.	27	$24,990
Astellas Pharma US Inc	19	$9,549
AstraZeneca(2 entities)	33	$495
Incyte Corporation	14	$366
E.r. Squibb & Sons, L.L.C.	10	$273
Johnson & Johnson(2 entities)	10	$223
Daiichi Sankyo Inc.	10	$172
Amgen	5	$155
Gilead(2 entities)	9	$151
Bayer	10	$148
Genentech USA, Inc.	5	$136
GSK	7	$132
Pfizer	3	$125
Karyopharm Therapeutics Inc.	8	$120
Beigene USA, Inc.	7	$102
Dendreon Pharmaceuticals LLC	7	$98
ASD Specialty Healthcare, LLC	1	$94
Novartis	6	$82
Sanofi	4	$79
Pharmacyclics LLC, An Abbvie Company	5	$73
Puma Biotechnology, Inc.	4	$65
Bristol Myers Squibb	4	$60
Takeda Pharmaceuticals U.S.A., Inc.	2	$45
Regeneron Healthcare Solutions, Inc.	3	$45
Verastem, Inc.	3	$44
Merck	3	$44
AbbVie	2	$40
Lilly USA, LLC	2	$39
EMD Serono, Inc.	2	$34
Geron Corporation	2	$31
G1 Therapeutics, Inc.	2	$29
Acera Surgical, Inc.	1	$26
Sirtex Medical Inc	1	$24
Adaptive Biotechnologies Corporation	1	$20
Jazz Pharmaceuticals Inc.	1	$19
Nuvation Bio Inc.	1	$19
Pharmacosmos Therapeutics Inc.	1	$18
Sumitomo Pharma America, Inc.	1	$18
Agios Pharmaceuticals, Inc.	1	$17
Rigel Pharmaceuticals, Inc.	1	$15
Teva Pharmaceuticals USA, Inc.	1	$13
Heron Therapeutics, Inc.	2	$12
Ipsen Biopharmaceuticals, Inc	1	$11
Exelixis Inc.	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

PADCEV$24,627
XTANDI$6,362
ELIQUIS$118

How this compares

$38,261 in reported general payments places this provider in the 90th percentile of 362 hematology & oncology providers in New Jersey.

See all hematology & oncology providers in New Jersey →

Medicare billing

Part B allowed, 2024

$351,347

Medicare patients

Services billed

19,062

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Belleville

Said SalehBelleville$43K
James OrsiniBelleville$24K
Robert SpiegelWestfield$864K
Amit PatelJersey City$770K
Joshua StraussSpringfield$739K
Charles FarberMorristown$609K
Michael ScolaMorristown$506K
Eshan PatelSomerville$420K
Arturo Loaiza-BonillaPennington$406K
Ashish ShahSpringfield$394K

See the full list for New Jersey →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →